Dyadic to Present at BioProcess International
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Pharmaceutical
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ETVANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE)...
Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
Significant progress made and well positioned for future growthLONDON, UK / ACCESSWIRE / September 13, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),...
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of...
Lucy Scientific Discovery Expands its Reach in the Global Wellness Market with BlueSky Wellness Acquisition
VANCOUVER, BC / ACCESSWIRE / September 12, 2023 / Lucy Scientific Discovery Inc. (NASDAQ:LSDI), a publicly traded company focused on...
Orthofix Announces Leadership Changes
Catherine Burzik Appointed Interim Chief Executive Officer Geoffrey Gillespie Appointed Interim Chief Financial Officer Puja Leekha Appointed Interim Chief Legal...
GoodCap Pharmaceuticals Announces Publication of Positive Results from Two Studies Relating to GoodCap’s Lead Drug Candidate
Toronto, Ontario--(Newsfile Corp. - September 12, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a leading biopharmaceutical company focused...
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeJaguar intends to pursue...
Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023
Company reaches major strategic inflection point, with operations and revenue ramp-up underwayInaugural 2026 guidance introduced; target to achieve:More than $180...
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce that following...
TRIANA Biomedicines Announces the Appointments of Vito Palombella as Chief Scientific Officer and Reza Mazhari as Chief Business Officer
Appointments strengthen the leadership team and deepen expertise in drug discovery, oncology research, and strategic partnershipsDr. Brian Jones appointed to...
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate...
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
Nominations recognize innovative development of AVERSA™ abuse-deterrent transdermal technologyORLANDO, FL / ACCESSWIRE / September 12, 2023 / Nutriband Inc. (the...
SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types.BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE)...
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were...
Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary...
Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary...
GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies Group
GelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security MarketMIAMI, Sept. 12, 2023 (GLOBE...
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancerNEW...